Boston Financial Mangement LLC Sells 158 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Boston Financial Mangement LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,391 shares of the company’s stock after selling 158 shares during the period. Boston Financial Mangement LLC’s holdings in IDEXX Laboratories were worth $989,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Concurrent Investment Advisors LLC raised its position in IDEXX Laboratories by 36.7% in the fourth quarter. Concurrent Investment Advisors LLC now owns 861 shares of the company’s stock worth $356,000 after purchasing an additional 231 shares in the last quarter. Alberta Investment Management Corp raised its position in IDEXX Laboratories by 25.3% in the fourth quarter. Alberta Investment Management Corp now owns 10,900 shares of the company’s stock worth $4,506,000 after purchasing an additional 2,200 shares in the last quarter. Lyell Wealth Management LP raised its position in IDEXX Laboratories by 0.3% in the fourth quarter. Lyell Wealth Management LP now owns 21,123 shares of the company’s stock worth $8,733,000 after purchasing an additional 72 shares in the last quarter. TimesSquare Capital Management LLC raised its position in IDEXX Laboratories by 31.9% in the fourth quarter. TimesSquare Capital Management LLC now owns 193,516 shares of the company’s stock worth $80,007,000 after purchasing an additional 46,857 shares in the last quarter. Finally, Waycross Partners LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth about $13,411,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock valued at $6,161,276 over the last quarter. Corporate insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of several recent research reports. Bank of America increased their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Finally, StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $452.89 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market cap of $37.09 billion, a P/E ratio of 42.45, a P/E/G ratio of 3.38 and a beta of 1.37. The firm has a 50 day simple moving average of $431.19 and a 200 day simple moving average of $452.42. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.